ICU Medical (NASDAQ:ICUI) Releases FY 2024 Earnings Guidance

ICU Medical (NASDAQ:ICUI) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.400-5.700 for the period, compared to the consensus earnings per share estimate of 5.220. The company issued revenue guidance of -. ICU Medical also updated its FY24 guidance to $5.40-5.70 EPS.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ICUI shares. Jefferies Financial Group assumed coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. Raymond James increased their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. KeyCorp raised their price objective on ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.25.

ICU Medical Stock Performance

Shares of ICUI stock traded down $0.26 during mid-day trading on Tuesday, reaching $178.01. The stock had a trading volume of 267,471 shares, compared to its average volume of 273,286. The firm’s 50 day simple moving average is $175.56 and its 200 day simple moving average is $141.16. The firm has a market cap of $4.35 billion, a PE ratio of -61.05 and a beta of 0.66. ICU Medical has a one year low of $79.85 and a one year high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel Woolson sold 2,502 shares of ICU Medical stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,502 shares of company stock valued at $8,445,976. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.